Inhibikase Therapeutics, Inc. (IKT)

Last Closing Price: 2.50 (2026-09-04)

EBITDA Margin (Quarterly)

EBITDA Margin: Earnings before interest, taxes, depreciation and amortization as a portion of total revenue. Calculated as: EBITDA / Total Revenues

Inhibikase Therapeutics, Inc. (IKT) EBITDA Margin data is not available.

Figures for fiscal quarter ending 2026-06-30
Income Statement Financials
--
$-19.59M
--
--
$21.05M
$-21.05M
$1.46M
$-19.59M
$-19.59M
$-19.59M
$-19.59M
$-19.59M
$-19.59M
$-21.05M
$-21.05M
174.57M
174.57M
$-0.11
$-0.11
Balance Sheet Financials
$162.34M
--
$1.24M
$163.59M
$10.26M
--
--
$10.26M
$153.33M
$153.33M
$153.33M
132.03M
Cash Flow Statement Financials
$-24.50M
$-86.39M
$2.88M
$139.22M
$31.21M
$-108.01M
$10.91M
--
--
Fundamental Metrics & Ratios
15.82
--
--
--
--
--
--
--
EBITDA Margin
--
--
--
$-24.50M
--
--
--
--
--
--
--
-12.78%
-12.78%
-11.98%
-12.78%
$1.16
$-0.14
$-0.14